Improved Coronary Vasodilatatory Capacity by H.E.L.P. Apheresis: Comparing Initial and Chronic Treatment

Abstract: Hypercholesterolemia impairs endothelial function and subsequently decreases coronary vasodilatatory capacity. We examined the quantitative effects of one single LDL apheresis on vasodilatatory capacity. Using N-13 ammonia as a tracer for dynamic quantitative positron emission tomography (PET), mean myocardial perfusion measurements were carried out before and 20 h later after LDL apheresis, both under resting conditions and after pharmacological vasodilatation with dipyridamole. LDL apheresis was carried out using the heparin induced extracorporeal LDL precipitation (H.E.L.P.) procedure. We examined 47 patients (12 women and 35 men), with angiographically-proven coronary artery disease. All of them suffered from hypercholesterolemia. Of the patients, 35 received a chronic weekly H.E.L.P. procedure (group A), while H.E.L.P. procedure treatment was started for the first time in 12 patients, who were subsequently enrolled in a chronic apheresis program (group B). H.E.L.P. apheresis was combined with cholesterol lowering drugs in all patients. Both groups underwent positron emission tomography twice (prior to LDL apheresis and 20 h later). In group A, LDL cholesterol levels decreased from 175 ± 50 mg/dL to 60 ± 21 mg/dL immediately after H.E.L.P. (77 ± 25 mg/dL before the second PET). Corresponding values for fibrinogen levels were 287 ± 75 mg/dL to 102 ± 29 mg/dL (155 ± 52 mg/dL), minimal coronary resistance dropped from 0.56 ± 0.20 to 0.44 ± 0.17 mm Hg × 100 g × min/mL (P < 0.0001). Plasma viscosity decreased by 7.8%. In group B, LDL cholesterol decreased from 187 ± 45 mg/dL to 75 ± 27 mg/dL (85 ± 29 mg/dL) and fibrinogen from 348 ± 65 mg/dL to 126 ± 38 mg/dL (168 ± 45 mg/dL). Minimal coronary resistance was reduced from 0.61 ± 0.23 to 0.53 ± 0.19 mm Hg × 100 g × min/mL (P < 0.01). Plasma viscosity was observed to decrease by 7.6%. The strong LDL drop in patients under chronic H.E.L.P. treatment has a significant impact on coronary vasodilatatory capacity within 20 h leading to an improved overall cardiac perfusion. Nearly the same effect can be seen in patients after their first H.E.L.P. treatment.